Edwards Lifesciences Corp (NYSE:EW)

CAPS Rating: 4 out of 5

A global provider of products and technologies designed to treat advanced cardiovascular disease. The Company focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.

Results 1 - 16 of 16

Recs

0
Member Avatar FrankoJames (93.63) Submitted: 12/19/2014 10:19:07 PM : Underperform Start Price: $133.22 EW Score: +0.91

Russo, this stock is the serpent of the medial device industry; I hope that the people living in this world get and stay healthy from this point forth, so I am giving this equity the coveted red thump in my CAPS game. Enjoy.

Recs

0
Member Avatar LoveMeSomeGreen (98.97) Submitted: 11/22/2013 10:26:19 AM : Outperform Start Price: $64.53 EW Score: +90.11

Contrarian buy - charts haven't looked good, but I think it could be in for a reversal.

Was recently featured in a great article on seeking alpha detailing stocks that have outperformed the market w/ a low beta.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/26/2013 7:50:39 PM : Outperform Start Price: $72.40 EW Score: +56.74

Long. Medical device company is growing nicely, has a good balance sheet and trading at a fair valuation.

Recs

0
Member Avatar ROEoutshinesGOLD (99.41) Submitted: 7/12/2013 11:50:09 AM : Outperform Start Price: $67.23 EW Score: +66.42

EW announces that the District Court of Mannheim, Germany found that MEDTRONIC infringes EWs' Spenser patent for trans-catheter heart valve technology.
Says the court granted an injunction prohibiting the sale of CoreValve and CoreValve Evolut systems in Germany, a recall of these products, and an accounting for past damages.
___________________________________________________________________________________________________

S&P 4**** STAR

This company makes and markets a comprehensive line of products and services to treat late-stage cardiovascular disease.

We view EW's TAV and surgical heart valve businesses as defensive lines that should continue to post solid results. In this regard, we were encouraged by the strong, late-2011 U.S. launch of the SAPIEN. Moreover, that launch was only for its implantation in patients unable to undergo open-heart surgery via the trans-femoral approach. We believe the potential patient population expanded with the FDA's later approvals for TA implantation and implantation in high-risk patients. Looking ahead, we believe the TA training delay by some centers is temporary and the consignment conversion will mask the procedure count. We expect the procedure count will continue to rise at a still-healthy clip over the long term. We also view potential Japanese approval for the next-generation SAPIEN XT as a catalyst.

We forecast revenue growth of 8.5% in 2013.
We see this growth mainly driven by a 27%-28% increase in trans-catheter aortic valve (TAV) revenues, amid a still-strong demand for TAV implantation in the U.S. However, while U.S. TAV sales should benefit from the new hospital implantation centers and hospitals stocking the new SAPIENs for trans-apical (TA) implantation, 20 centers delayed TA training. EW also notes that some centers were realizing capacity constraints and certain others are questioning profitability based on regional Medicare reimbursement. In addition, reported sales will likely be pressured in the second half, on the conversion of hospitals that initially placed stocking orders and implanted 20-30 TAVs to consignment accounts. Meanwhile, we look for 2%-3% growth in constant currency for surgical heart valve and critical care product sales.

We expect gross margins to widen in 2013, mainly on an improving product mix, while the operating cost ratio declines, despite the 2013 onset of the U.S. medical device tax.

We see adjusted EPS of $3.10 in 2013, versus $2.69 in 2012, and we look for $3.63 in 2014.

Our 12-month target price of $80 reflects a multiple of 29X our 2013 EPS estimate, below the stock's recent averages due to near-term headwinds we see.

Risks to our recommendation and target price include market share losses in key product categories and inability to successfully commercialize products in the pipeline.

Recs

0
Member Avatar gotchey (< 20) Submitted: 5/18/2013 12:27:47 AM : Outperform Start Price: $67.00 EW Score: +73.32

Was hit to hard for earnings and getting a new CEO.

Recs

0
Member Avatar NHWeston (< 20) Submitted: 9/7/2012 10:40:51 AM : Outperform Start Price: $107.23 EW Score: -20.38

As the "bionic-being" lifestyle becomes more achieveable, EW will lead the way in "auto-heart" technology.

Recs

0
Member Avatar schmidty412 (< 20) Submitted: 7/28/2012 5:58:15 AM : Outperform Start Price: $105.22 EW Score: -23.88

The Saphien heart valve is a monster piece of technology. It gives a surgery option to a large set of older people who couldn't have open heart. There isnt a competitor in this space, and hospitals worldwide are having to look to cut costs. Saphien is much less invasive, which means faster recovery. It was a technology developed in-house as is most of their products.

Recs

0
Member Avatar gorjo (< 20) Submitted: 5/10/2011 3:11:08 AM : Outperform Start Price: $88.20 EW Score: -3.30

Innovative new technology. Industry leader.

Recs

0
Member Avatar lacostakid (74.54) Submitted: 12/31/2010 2:07:08 PM : Outperform Start Price: $81.53 EW Score: -1.26

good sales and earnings growth

Recs

0
Member Avatar blocksofstock (< 20) Submitted: 10/18/2010 2:29:57 PM : Outperform Start Price: $67.00 EW Score: +22.30

Pipeline pdts. + candidate to be bought

Recs

0
Member Avatar WilliamCrook2007 (< 20) Submitted: 11/20/2008 2:47:03 PM : Outperform Start Price: $23.23 EW Score: +300.78

ibd

Recs

0
Member Avatar robo2011 (37.11) Submitted: 7/20/2008 11:32:25 PM : Underperform Start Price: $33.13 EW Score: -230.60

Overvalued and at the top of a 52 week high, this stock is ripe and ready for a fall.

Recs

0
Member Avatar jetlith (37.31) Submitted: 7/3/2008 4:06:35 PM : Underperform Start Price: $30.79 EW Score: -261.43

gone up wayyyyyy too high, especially in this bear market.. and YoY eps has been dropping big. I expect a correction back down to the 40's.

Recs

0
Member Avatar ScreenerStizBear (82.80) Submitted: 6/26/2008 2:29:59 PM : Underperform Start Price: $31.15 EW Score: -259.25

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recs

0
Member Avatar joelima (< 20) Submitted: 4/11/2008 4:08:21 PM : Outperform Start Price: $23.12 EW Score: +410.68

Great pipeline

Recs

3
Member Avatar NetscribeMedDevs (96.88) Submitted: 2/26/2007 7:51:36 AM : Outperform Start Price: $25.92 EW Score: +359.97

Cardiovascular diseases is the number one cause of death world wide and is among the top three diseases in terms of health care spending in nearly every country. In the U.S. alone it is slated to affect 7 million people annually and the number is more or less same in countries around the world. Edward life systems operate in this area providing products and technology that caters to advanced cardiovascular diseases.

The company operates through five product lines namely Heart valve therapy, Critical care, Cardiac Surgery system, Vascular and other distribution products. The company is the market leader in the $1.1 billion heart valve market, which contributes about 48% of total revenue. Critical care chips in with 32% and the rest three segments contribute the rest almost equally. The company also has a spread out geographical presence with revenues coming from North America, Europe, Japan and Other International Markets in the proportion 50%, 22%, 18% and 10% respectively.

The heart valve market is undergoing a shift from mechanical valves to tissue-based valves, which strengthens Edward’s position, as the company is traditionally strong in the segment. The market for such valves is expect to grow at 7% annual, but Edward’s unique position puts it in a 9% per annum growth track as it has a first mover advantage. Also Stent products are going to revolutionalise the manner, in which cardiovascular diseases are treated, and the company with new products introduced in this segment is trying to make the most of the opportunity. The future thus looks promising for the company, as they have caught the tide at the right time and at the right place. Now all that is left is to sail the course.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement